Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
JHPCYDrugs in Pipeline
32
Phase 3 Programs
14
Upcoming Catalysts
6
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
6 upcoming, 1 past
Remimazolam Tosilate
General Anesthesia
Propofol
Anesthesia for Elective Surgery Patients
SHR-1209
Primary Hypercholesterolemia
SHR6390
Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer
JSKN016 Injection
Triple Negative Breast Cancer
SHR7280 tablets
Uterine Fibroids With Menorrhagia
SHR-A1811
HER2 Expression / Amplification in Patients With Biliary Tract Cancer
Pyrotinib
HER2-positive Breast Cancer
Hetrombopag Olamine
Severe Aplastic Anemia
SHR0302
Rheumatoid Arthritis
HRS-4642 + AG
KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting
Hetrombopag
Chemotherapy-Induced Thrombocytopenia
HR17031 injection
Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs
apatinib
Non-Small-Cell Lung Cancer
SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316
Advanced Non-small Cell Lung Cancer
HRS-9190; under Inhalational Anesthesia
Neuromuscular Blockade
Tegileridine Fumarate lnjection
Abirritation in the ICU
Bupivacaine Liposome Injection
Local Analgesia Via Nerve Block
SHR4640 ；Febuxostat
Primary Gout and Hyperuricemia
SHR-3167 Injection
Diabetes Mellitus, Type 2
HRS-4508+ Capecitabine
Solid Tumor
HRS-9190
Neuromuscular Blockade
HR19042 Capsules
IgA Nephropathy
FRSW117
Severe Hemophilia A
HRS-4508 tablet
Lung Cancer
Famitinib
Colorectal Cancer
SHR-1210
Nasopharyngeal Carcinoma
SHR-A1811 Injection
Recurrent or Metastatic Cervical Cancer
HS-20093 for Injection
Prostate Cancer
KN046
Esophageal Squamous Cell Carcinoma
SHR-3167
Type 2 Diabetes Mellitus
SHR-4394
Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Remimazolam Tosilate | Phase 3 | General Anesthesia | - | - |
Propofol | Phase 3 | Anesthesia for Elective Surgery Patients | - | - |
SHR-1209 | Phase 3 | Primary Hypercholesterolemia | - | - |
SHR6390 | Phase 3 | Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer | - | - |
JSKN016 Injection | Phase 3 | Triple Negative Breast Cancer | - | - |
SHR7280 tablets | Phase 3 | Uterine Fibroids With Menorrhagia | - | - |
SHR-A1811 | Phase 3 | HER2 Expression / Amplification in Patients With Biliary Tract Cancer | - | - |
Pyrotinib | Phase 3 | HER2-positive Breast Cancer | - | - |
Hetrombopag Olamine | Phase 3 | Severe Aplastic Anemia | - | - |
SHR0302 | Phase 3 | Rheumatoid Arthritis | - | - |
HRS-4642 + AG | Phase 3 | KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting | - | - |
Hetrombopag | Phase 3 | Chemotherapy-Induced Thrombocytopenia | - | - |
HR17031 injection | Phase 3 | Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs | - | - |
apatinib | Phase 3 | Non-Small-Cell Lung Cancer | - | - |
SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316 | Phase 2 | Advanced Non-small Cell Lung Cancer | - | - |
HRS-9190; under Inhalational Anesthesia | Phase 2 | Neuromuscular Blockade | - | - |
Tegileridine Fumarate lnjection | Phase 2 | Abirritation in the ICU | - | - |
Bupivacaine Liposome Injection | Phase 2 | Local Analgesia Via Nerve Block | - | - |
SHR4640 ；Febuxostat | Phase 2 | Primary Gout and Hyperuricemia | - | - |
SHR-3167 Injection | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
HRS-4508+ Capecitabine | Phase 2 | Solid Tumor | - | - |
HRS-9190 | Phase 2 | Neuromuscular Blockade | - | - |
HR19042 Capsules | Phase 2 | IgA Nephropathy | - | - |
FRSW117 | Phase 2 | Severe Hemophilia A | - | - |
HRS-4508 tablet | Phase 2 | Lung Cancer | - | - |
Famitinib | Phase 2 | Colorectal Cancer | - | - |
SHR-1210 | Phase 2 | Nasopharyngeal Carcinoma | - | - |
SHR-A1811 Injection | Phase 2 | Recurrent or Metastatic Cervical Cancer | - | - |
HS-20093 for Injection | Phase 2 | Prostate Cancer | - | - |
KN046 | Phase 2 | Esophageal Squamous Cell Carcinoma | - | - |
SHR-3167 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
SHR-4394 | Phase 2 | Prostate Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's drug pipeline?→
CatalystAlert tracks 32 drug candidates in Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's (JHPCY) pipeline across Phase 3, Phase 2. Its lead program is Remimazolam Tosilate (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's next FDA catalyst?→
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's (JHPCY) next tracked catalyst is a Phase 2 expected July 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track JHPCY biotech catalysts?→
Add JHPCY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.